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Abstract
Purpose Atherosclerotic plaque development and progression signifies a complex inflammatory disease mediated by a multitude
of proinflammatory leukocyte subsets. Using single photon emission computed tomography (SPECT) coupled with computed
tomography (CT), this study tested a new dual-isotope acquisition protocol to assess each radiotracer’s capability to identify
plaque phenotype and inflammation levels pertaining to leukocytes expressing leukocyte function-associated antigen-1 (LFA-1)
and the leukocyte subset of proinflammatory macrophages expressing somatostatin receptor subtype-2 (SST2). Individual
radiotracer uptake was quantified and the presence of corresponding immunohistological cell markers was assessed.
Methods Human symptomatic carotid plaque segments were obtained from endarterectomy. Segments were incubated in dual-
isotope radiotracers [111In]In-DOTA-butylamino-NorBIRT ([111In]In-Danbirt) and [99mTc]Tc-[N0–14,Asp
0,Tyr3]-octreotate
([99mTc]Tc-Demotate 2) before scanning with SPECT/CT. Plaque phenotype was classified as pathological intimal thickening,
fibrous cap atheroma or fibrocalcific using histology sections based on distinct morphological characteristics. Plaque segments
were subsequently immuno-stained with LFA-1 and SST2 and quantified in terms of positive area fraction and compared against
the corresponding SPECT images.
Results Focal uptake of co-localising dual-radiotracers identified the heterogeneous distribution of inflamed regions in the
plaques which co-localised with positive immuno-stained regions of LFA-1 and SST2. [
111In]In-Danbirt and [99mTc]Tc-
Demotate 2 uptake demonstrated a significant positive correlation (r = 0.651; p = 0.001). Fibrous cap atheroma plaque phenotype
correlated with the highest [111In]In-Danbirt and [99mTc]Tc-Demotate 2 uptake compared with fibrocalcific plaques and patho-
logical intimal thickening phenotypes, in line with the immunohistological analyses.
Conclusion A dual-isotope acquisition protocol permits the imaging of multiple leukocyte subsets and the pro-inflammatory
macrophages simultaneously in atherosclerotic plaque tissue. [111In]In-Danbirt may have added value for assessing the total
inflammation levels in atherosclerotic plaques in addition to classifying plaque phenotype.
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Introduction
Atherosclerosis is derived from an inflammatory cycle that
forms in response to the deposition of cholesterol-rich, apoli-
poprotein B-containing lipoproteins in the intimal layer of the
arterial wall [1]. Inflammation controls all stages of the disease
starting from the initiating atheroma development to the ad-
vanced, and potentially rupture-prone, plaque. Inflammation
is instrumental in causing the clinical complications resulting
in life-threatening stroke and myocardial infarction [2].
Detection of this inflammatory activity is a high clinical pri-
ority. If the atherosclerosis-associated inflammation can be
detected early, a considerable reduction in the occurrence of
these cardiovascular events could be made possible.
From the initiating phase of the disease, leukocytes, includ-
ing monocyte-derived macrophages, lymphocytes and neutro-
phils, adhere to activated endothelium and are recruited into
the developing atheroma [3]. The proinflammatory leukocytes
elicit a cascade of biological processes which renders the
plaque susceptible to structural disruptions including fibrous
cap ruptures [4]. Following rupture, exposure of the
thrombogenic plaque core to blood components can result in
catastrophic cardiovascular events [5]. The search for methods
that can specifically target the inflammatory activity in athero-
sclerotic tissue and identify the high-risk vulnerable plaque
phenotype addresses a clinical need [6].
Molecular imaging techniques including positron emission
tomography (PET) and single photon emission computed to-
mography (SPECT) have the unique capability to target spe-
cific biological processes at the molecular level. Numerous
radiotracers, capable of targeting leukocytes and the inflam-
matory subsets, have been developed and imaged in human
atherosclerotic plaque vessels [7]. [111In]In-DOTA-
butylamino-NorBIRT also known as [111In]In-Danbirt is a
novel radiotracer which can specifically target the leukocytes
which express leukocyte function-associated antigen-1 (LFA-
1). The value of this radiotracer has been initially demonstrat-
ed in in vivo animal studies utilising atherosclerosis disease
models and also in a human atherosclerotic plaque case [8, 9].
Targeted imaging of atherosclerotic plaque with [68Ga]Ga-
DOTA-[Tyr3]octreotate, a somatostatin receptor subtype 2
(SST2)–targeting radiotracer, detects the presence of activated
(proinflammatory) macrophages [10]. The clinical utilisation
of this radiotracer has revealed its ability to achieve more focal
imaging of inflamed atherosclerotic plaques in comparison to
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) and thereby
presenting another viable radiotracer [10–12]. Clinical studies
indicated that the detection of proinflammatory macrophages
with a SST2 targeting radiotracer could help discriminate cul-
prit plaques which have an overall higher uptake [10, 11].
Notwithstanding, there are conflicting results reported for this
radiotracer. For example, comparing symptomatic culprit ves-
sels to the contralateral vessels in the carotid vasculature can
result in little to no differences in terms of uptake levels [13,
14]. The detection of ‘culprit’ inflamed vessels is partially
impeded by the paucity of information linking radiotracer up-
take with respect to the specific plaque phenotype.
Furthermore, the simultaneous use of two radiotracers,
targeting different molecular processes, with dual-isotope ac-
quisition SPECT imaging has provided an enhancement in the
understanding of specific diseases [15–17]. The utilisation of
a dual-isotope acquisition protocol for atherosclerotic plaque
tissue assessment may also provide improved information and
in terms of aiding the detection of specific plaque phenotype.
In this regard, this study aims to assess the added value of
simultaneously targeting all leukocytes expressing LFA-1
and the subset of proinflammatory macrophages expressing
SST2 in order to identify plaque phenotype. To investigate
this, a dual-isotope acquisition protocol of [111In]In-Danbirt
and [99mTc]Tc-[Asp,Tyr]-octreotate also known as [99mTc]Tc-
Demotate 2 [18] is utilised to image ex vivo human ca-
rotid artery plaques. Additionally, the two radiotracers
are compared to investigate if targeting all leukocytes
provides pertinent information regarding the inflamma-
tory status of the plaque that could be overlooked with
current clinical protocols targeting the subset of proin-
flammatory macrophages alone.
Materials and methods
Study design
A cross-sectional molecular imaging study was performed
with excised human carotid plaques. This exploratory research
examines the uptake of two radiotracers pertaining to inflam-
matory populations involved in plaque progression. The
plaque samples were obtained from seven atherosclerotic/
symptomatic patients through endarterectomy procedures in
the Erasmus MC, Rotterdam, The Netherlands, in a manner
that conformed to the declaration of Helsinki and was ap-
proved by the hospital’s ethical research committee (MEC
2008-147). The carotid plaques were divided into segments
of 2-mm thickness (n = 23) for SPECT/CT imaging
followed by immunohistochemistry. In another set of
experiments, adjacent carotid endarterectomy (CEA)
segments (n = 7) were sectioned for autoradiography
followed by immunohistochemistry.
Radiolabelling
To target the two plaque’s inflammatory cell populations,
[111In]In-Danbirt (MW = 886.5 g/mol) [9] and [99mTc]Tc-
Demotate 2 [18] were used (Fig. 1). Each peptide was
radiolabelled with a molar activity of 100 MBq/nmol, the
radiochemical purity was > 90%, and the incorporation yield
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was > 99%, as determined by high-pressure liquid chromatog-
raphy and instant thin-layer chromatography on silica gel. For
[111In]In-Danbirt Quenchers (3.5 mM ascorbic acid, 3.5 mM
gentisic acid, 10 mM methionine) were present during label-
ling to prevent radiolysis of the radiotracer [19]. The radio-
tracers were mixed in a solution of phosphate-buffered saline
(PBS) containing 0.1% v/v bovine serum albumin (BSA). The
plaque samples were incubated in a mixed solution of the 2
radiotracers for 1 h at room temperature. The plaque samples
were then washed in PBS five times and assembled on a
sealed Perspex sample holder for scanning (Fig. 2).
Dual-isotope SPECT/CT imaging
For SPECT/CT imaging a VECTor5/CTsystem (MILabs B.V.
Utrecht, The Netherlands) was used equipped with a high-
energy ultra-high resolution mouse (HE-UHR-M) collimator.
The system equipped with this collimator yields a 0.5 mm
reconstructed SPECT resolution and a SPECT sensitivity of
~ 0.3% [20, 21]. Each scan was acquired in list mode using the
same scan parameters, spiral scan mode [22], and fine step
mode at 30 s per bed position yielding a total acquisition time
of 90 min for a field of view of 26 mm in diameter and 48 mm
in length. This permitted scanning six 2-mm plaque segments,
placed in the sample holder, during a single scan. For the CT,
scanner settings were identical for all scans. Ultra-focus mag-
nification was applied with a full scan angle, at 0.24 mA,
50 kV and 75 ms yielding a total scan time of 15 min. The
scans were reconstructed using filtered back projection at a
resolution of 20 μm and downsampled to a reconstructed res-
olution of 80 μm for registration to SPECT scans.
To accomplish quantification of 99mTc and 111In from dual
isotope acquisitions, two separate reconstructions were per-
formed. For 99mTc, a width of 20% of the gamma photopeak
Fig. 2 a Carotid plaque sample sectioned into 2-mm segments, (b) incu-
bation step involved immersing segment in mixture of dual-radiotracers
[111In]In-Danbirt) and [99mTc]Tc-Demotate 2 and (c) live and x-ray view
of plaque segments (2 mm) mounted on a custom-made holder for dual-
isotope acquisition SPECT/CT scanning
Fig. 1 a Schematic of the two radiotracers targeting the receptors of
leukocytes expressing leukocyte function-associated antigen-1 (LFA-1)
and proinflammatory macrophages expressing somatostatin receptor
subtype-2 (SST2). Chemical structures of the two radiotracers (b)
[111In][In-DOTA-butylamino-NorBIRT] ([111In]In-Danbirt) and (c)
[[99mTc]Tc-[N0–14,Asp
0,Tyr3]octreotate ([99mTc]TcTc-Demotate 2)
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at 140 keV was incorporated in the reconstruction. For 111In,
two photopeak windows were set incorporating a width of
20% of the each gamma photopeak at 171 and 245 keV
[23]. For scatter correction the triple-energy-window method
was [24] applied to each photo peak. Phantom experiments
with dual-isotope acquisitions for 99mTc and 111In were per-
formed using the small-animal SPECT phantom SPECT IQ
phantom which verified that the cross-talk within the relevant
energy ranges was negligible [25].
SPECT scans were reconstructed at 0.2-mm voxel size
using the similarity regulated ordered subset expectation
maximisation (SROSEM) algorithm [22]. For this, 9 itera-
tions, 128 subsets and a 3D Gaussian post filter of 0.5 mm
(FWHM) were utilised. The VECTor5/CT system was cali-
brated to a standard of known activity that was measured in a
dose calibrator, for absolute SPECT quantification for both
radionuclides. All analysis of SPECT/CT scans was per-
formed using PMOD (PMOD Technologies LLC, Zürich,
Switzerland, Version 3.4). After imaging, the tissue segments
were embedded in Tissue-Tek medium and stored at − 80 °C
for immunohistological analysis after the radioactivity
contained in the samples had decayed.
Immunohistological analyses
Each 2-mm plaque segment was cryo-sectioned into four
500-μm blocks in line with the SPECT resolution. Within
each 500-μmblock, sequential adjacent sections of 5 μmwere
made which overall yielded a total of 262 sections for quanti-
fication and analysis with respect to the SPECT/CT scan data.
Sections were immunohistochemically stained with anti-LFA-
1 (mouse anti-human CD11a 1:100 Biorad, MCA1848 clone
38), and anti-SST2A (human tissue: rabbit anti-human
SSTR2A 1:50, clone UMB1, Abcam). Haematoxylin and eo-
sin staining was used to determine the plaques overall struc-
tural morphology. The slides were photographed using a
NanoZoomer Digital slide scanner (Hamamatsu, Photonics
K.K). All images were exported to BioPix iQ 3.3.5 software
for quantitative analysis. The areas of positively stained LFA-
1 and SST2 were quantified using the dedicated hue, satura-
tion and brightness selection tool, and positive areas were
measured as a percent fraction of the total plaque tissue area.
Plaque classification
The twenty-three carotid plaque segments were classified into
3 groups according to the American Heart Association (AHA)
plaque classification [4], based on distinct morphological
characteristics, identified with histology. Segments with path-
ological intimal thickening (n = 4, 17%) contained areas of
inflammatory infiltration without necrotic tissue and were
present in the bifurcation and internal carotid region. The fi-
brous cap atheroma segments (n = 9, 39%) morphologically
consisted of a well-formed necrotic core and an overlying
fibrous cap containing a high infiltration of inflammatory cells
and were mainly found in the internal and common carotid
regions. The fibrocalcific segments (n = 10, 43%) contained
large areas of calcification within the necrotic core and were
all located in the bifurcation region.
Autoradiography
Segments of the carotid plaques, adjacent to those used for
scanning, were cryo-sectioned at 10 μm and examined by
ex vivo autoradiography and immunohistochemistry. Slides
were washed in a washing buffer consisting of 1 M Tris-HCl
(pH = 7.6) containing 0.25% v/v BSA for 10 min. The sam-
ples were incubated with 80 μL of radiotracer (10−9 M), with
and without excess (10−6 M) matching unlabelled tracer for
blocking. Slides were then washed and allowed to dry in an
incubator at 37 °C. High sensitivity phosphor screens were
placed over the tissue sections for 48 h, after which the screens
were read using a Packard Cyclone (Perkin Elmer) resolution
600 DPI. Quantification of the plaque sections was performed
in terms of digital light units per mm2 (DLU/mm2) using
Optiquant (Perkin Elmer).
Statistical analysis
Statistical analysis was performed using IBM SPSS statistics
21. Shapiro–Wilk tests were performed to assess the distribu-
tion of the data and select the most appropriate statistical test.
Pearson’s correlation (r) and Spearman’s rho correlation (rs)
were used to compare the correlation between the uptake
levels of the radiotracers. A Mann–Whitney U test was used
for non-parametric datasets to compare differences between
uptake and positive area fraction for the three plaque morphol-
ogy groups.
Results
Expression of LFA-1 and SST2 in carotid plaque
segments
Figure 3 illustrates the distinct morphological characteristics
and positive immuno-stained regions of LFA-1 and SST2 in
three plaque phenotypes classified as pathological intimal
thickening, fibrous cap atheroma and fibrocalcific. In the in-
flamed fibrous cap atheroma phenotype, immunohistological
analyses revealed large clusters of co-localising LFA-1- and
SST2-expressing inflammatory cells concentrated in the ath-
eroma, at the fibrous caps and along shoulders (Figs. 3f, h and
4c, d). Quantification of the areas with positive immuno-
staining for LFA-1 and SST2, within the representative 4 cryo-
sections taken at intervals of 500 μmwithin each of the 2-mm
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plaque segments, revealed that the overall area fraction of
LFA-1-positive leukocytes was significantly larger in compar-
ison with the area fraction positive for SST2-expressing mac-
rophages independent of plaque phenotype. A large degree of
variation was detected for fibrous cap atheroma segments in
terms of the degree of positive LFA-1, reflecting the diverse
inflammation status associated with this phenotype. The fi-
brous cap atheroma segments contained a significantly higher
degree of inflammatory cells expressing LFA-1 compared
with the fibrocalcific plaque segments and the pathological
intimal thickening segments (Fig. 5a). For SST2, fibrous cap
atheroma segments and fibrocalcific segments contained com-
parable area fraction levels of SST2-positive cells.
Pathological intimal thickening segments contained a signifi-
cantly lower amount of SST2-positive area (Fig. 5b).
Radiotracer targeting of LFA-1 and SST2 in different
plaque phenotypes assessed by SPECT
High-resolution SPECT images portray the local specificity of
the dual-radiotracer’s binding to inflamed regions in the
plaques which also co-localises with positive immuno-
stained regions of LFA-1 and SST2 (Fig. 3). An example of
the focal high uptake of both radiotracers in the atheroma core
and fibrous cap region of a fibrous cap atheroma plaque is
illustrated in the SPECT images in Fig. 4 whereby regions
of [111In]In-Danbirt uptake co-localised with [99mTc]Tc-
Demotate 2 uptake. The [111In]In-Danbirt uptake is signifi-
cantly higher compared with the [99mTc]Tc-Demotate 2 for
all plaque samples analysed in this cohort (p = 0.001). There
is a significant positive correlation in uptake between the ra-
diotracers targeting the cells expressing LFA-1 and SST2 re-
ceptors (r = 0.651; p = 0.001) as illustrated in Fig. 6.
Quantification of each radiotracer’s total uptake (MBq/g) in
each 2-mm plaque segment with distinct plaque phenotype
revealed that the highest uptake of [111In]In-Danbirt is corre-
lated to plaque phenotype with fibrous cap atheroma (20.39 ±
3.97MBq/g) (Fig. 7a). The uptake is significantly higher com-
pared with both the pathological intimal thickening (14.70 ±
3.23 MBq/g) and fibrocalcific plaque (14.05 ± 4.89 MBq).
For [99mTc]Tc-Demotate 2 the mean uptake is significantly
higher in the fibrous cap atheroma segments (7.98 ±
1.10 MBq/g) compared with the fibrocalcific segments
(6.36 ± 2.39 MBq/g) (Fig. 7b). However, a significant differ-
ence was not reached between the fibrous cap atheroma and
pathological intimal thickening (6.38 ± 2.23 MBq/g) for the
[99mTc]Tc-Demotate 2 uptake (p = 0.142).
Comparing the sections with and without excess (10−6 M)
radiotracer revealed the substantial reduction in uptake in the
CEA sections. The autoradiography analysis of [111In]In-
Danbirt and [99mTc]Tc-Demotate 2 uptake also revealed the
focal regions of high radiotracer binding in the fibrous cap
atheroma segments in line with the immuno-positive regions
for LFA-1 and SST2 respectively (Fig. 8).
Fig. 3 SPECT images of uptake for [111In]In-Danbirt (left panel 0–
37 MBq/ml) and [99mTc]Tc-Demotate 2 (right panel 0–17.5 MBq/ml)
and the corresponding immunohistological sections classified according
to plaque phenotype; pathological intimal thickening (a–d), fibrous cap
atheroma (e–h) and fibrocalcific (i–l) (scale bar = 1 mm)
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Discussion
In this study, a dual-isotope acquisition SPECT imaging pro-
tocol was tested to assess radiotracer uptake in distinct plaque
phenotypes pertaining to two inflammatory cell populations
involved in atherosclerosis. We demonstrated the unique ca-
pability of the [111In]In-Danbirt to identify inflamed plaque
phenotype using human carotid plaques acquired through end-
arterectomy procedures. The mean [111In]In-Danbirt and
[99mTc]Tc-Demotate 2 uptake was highest in fibrous cap ath-
eroma plaque compared with pathological intimal thickening
and fibrocalcific plaques. A comparison of the uptake for the
two radiotracers revealed that [111In]In-Danbirt uptake was
significantly higher compared with [99mTc]Tc-Demotate 2
Fig. 4 SPECT co-localisation of
radiotracer uptake (a) [111In]In-
Danbirt) and (b) [99mTc]Tc-
Demotate 2 and corresponding
immunohistochemistry sections
with positive immunostaining for
(c) LFA-1 and (d) SST2 in a
plaque segment classified with fi-
brous cap atheroma phenotype
(scale bar = 1 mm)
Fig. 5 Box-plot of percent area
fraction of positive immuno-
staining for (a) LFA-1 and (b)
SST2 in segments classified ac-
cording to plaque phenotype (PIT,
pathological intimal thickening;
FC atheroma, fibrous cap athero-
ma; F.calc, fibrocalcific)
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uptake for all plaque samples analysed in this cohort, indepen-
dent of plaque phenotype. These findings were in line with the
immunohistological findings, and detailed examination of the
corresponding immunohistological sections revealed co-
localisation with LFA-1- and SST2-expressing cells.
The atherosclerotic inflammatory activity is driven by mul-
tiple key leukocyte subsets including the monocyte-derived
macrophages, lymphocytes and neutrophils [26, 27]. In this
regard, it is important to detect the presence of all leukocyte
subsets, encapsulating the total inflammation activity, as a
means for early atherosclerotic disease detection and potential
prevention of adverse cardiovascular events [28]. SPECT im-
aging showed focal uptake of [111In]In-Danbirt in the carotid
plaque tissue which varied in accordance with the degree of
inflammation that was heterogeneously distributed throughout
the plaque as indicated by the co-localising areas of positive
immuno-staining for LFA-1. The overall higher degree of
[111In]In-Danbirt uptake compared with [99mTc]Tc-Demotate
2 uptake for all plaque samples analysed in this cohort is
indicative of the successful detection of all leukocytes which
are playing a key role in the disease progression. In a clinical
setting, PET scanning is the preferred methodology in athero-
sclerosis imaging in terms of nuclear medicine due to the
superior spatial resolution and quantification capabilities com-
pared with clinical SPECT. For example, Moto et al. recently
demonstrated that Danbirt labelled with the PET radioisotope
gallium-68 is highly stable in vitro in conditions that closely
emulate those found during in vivo tracer delivery [9]. For
clinical use, the equivalents to SPECT imaging with
[99mTc]Tc-Demotate 2 for targeting SST2-expressing proin-
flammatory macrophages in vivo are [68Ga]Ga-DOTA-TATE
and [64Cu]Cu-DOTA-TATE which have both been shown to
be potentially relevant tracers for plaque imaging with PET in
cardiovascular disease patients.
From a pathological point of view, the atherosclerotic
plaque composition is heterogeneous even within the same
phenotype as identified for the [111In]In-Danbirt uptake in
the fibrous cap atheroma segments. This is a consequence of
the fact that inflammation levels vary considerably depending
on the disease phase and inflammatory activity. Notably, this
large variation in inflammation intensity was less pronounced
in the [99mTc]Tc-Demotate 2 uptake, likely as proinflammato-
ry macrophages (SST2) represent a small subset of the inflam-
matory cells present in the plaque. While [111In]In-Danbirt
imaging alone is very informative regarding atherosclerotic
plaque phenotype detection, the ratio of [99mTc]Tc-Demotate
2 to [111In]In-Danbirt advocates a potential role for dual-
isotope acquisition in the assessment of plaque inflammation
advancing the understanding towards the atherosclerotic dis-
ease development. For example, in the fibrous cap atheroma
segments the ratio of [99mTc]Tc-Demotate 2 to [111In]In-
Danbirt is lower compared with the fibrocalcific segments.
This implicates a higher level of involvement of the other
leukocyte subsets with the proinflammatory macrophages in
the fibrous cap atheroma phenotype compared with the more
advanced fibrocalcific phenotype. In this regard, a dual-
isotope acquisition protocol could provide added diagnostic
Fig. 7 Box-plot of radiotracer
uptake (MBq/g) for (a) [111In]In-
Danbirt and (b) [99mTc]Tc-
Demotate 2 in each carotid plaque
segment type classified according
to plaque phenotypes. PIT, path-
ological intimal thickening; FC,
fibrous cap atheroma; F.calc,
fibrocalcific
Fig. 6 Positive correlation between [99mTc]Tc-Demotate 2 and [111In]In-
Danbirt and in terms of total uptake (MBq/g) per plaque segment
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benefit for the assessment of inflamed atherosclerotic vessels
which could be useful for patient-specific therapeutic
intervention.
Moreover, studies have reported the performance of
[111In]In-Danbirt in vivo utilising the ApoE−/−mouse model.
These studies provide evidence that the [111In]In-Danbirt is
adequately taken up in local athero-prone regions, including
the aortic arch. These atherosclerotic regions of uptake further
co-localise with immunohistochemistry LFA-1-expressing
cells [8]. Importantly, the myocardial uptake signal is suffi-
ciently low with respect to the background levels so as to not
interfere with the imaging quantification of the aorta’s inflam-
mation [8].
Pathological studies have classified the fibrous cap athero-
ma phenotype as the ‘culprit’ part of the vessel [29–31].
Interestingly, in this study the intensity of radiotracer uptake
correlated to plaque phenotype. The highest [111In]In-Danbirt
uptake (MBq/g) correlates to inflamed fibrous cap atheroma
plaque segments. This differentiates these highly inflamed
plaque segments from fibrocalcific and pathological intimal
thickening segments which are considerably less inflamed,
and considered to have a lower risk of rupture. Similarly, the
mean [99mTc]Tc-Demotate 2 uptake was also highest in the
fibrous cap atheroma segments and also significantly higher
compared with the fibrocalcific phenotype in line with the
immunohistochemistry. Notwithstanding, to make a distinc-
tion in specific atherosclerotic plaque phenotype and the iden-
tification of vulnerable plaque characteristics remains a chal-
lenge based on the current radiotracers used in the clinic [13,
32, 33]. For example, clinical studies have reported difficulty
in differentiating symptomatic carotid vessels compared with
the contralateral asymptomatic diseased side where there is a
high degree of disease present in the contralateral carotid ves-
sel [13]. Consequently, delineation of the culprit vulnerable
plaque is not always possible. The typical morphological fea-
tures of a vulnerable plaque have been determined from
pathological studies and can be characterised usingMRI scan-
ning. These include the presence of a large lipid-rich necrotic
core, an overlying thin fibrous cap layer and intraplaque
haemorrhage [34–36]. However, morphological plaque data
alone is also not enough for risk prediction of plaque rupture.
In this regard, combining a measurement of the inflammation
imaging [9] and the plaque morphology information from
MRImay permit assessing the degree of inflammation activity
coupled with vulnerable plaque characteristics in order to de-
lineate high-risk vessels [37, 38].
There are inherent limitations associated with this study
that must be taken into account. The clinical translational as-
pect of the dual-isotope acquisition imaging protocol utilised
in this ex vivo setting needs to be assessed in vivo. Notably,
the acquisition of SPECT/CT imaging involved using a HE-
UHR-M collimator which resulted in a considerably higher in-
plane resolution of 0.5 mm compared with the resolution ca-
pabilities of the clinical PET scanner which are approximately
10 times lower [33]. In a clinical setting, the opposite occurs
whereby PET resolution outperforms SPECT. Thus the PET
isotopes fluorine-18 and gallium-68 are more favourable in
the clinical setting compared with indium-111 or techne-
tium-99m, although there is no current option for dual-
isotope imaging with the PET isotopes. Moreover, in order
to incorporate a dual-isotope acquisition for SPECT imaging,
[99mTc]Tc-Demotate 2 was used simultaneously with
[111In]In-Danbirt in this study. In the clinical setting,
[68Ga]Ga-DOTA-TATE is utilised for PET imaging of SST2-
expressing proinflammatory macrophages. It is important to
take into account the application of different analogue radio-
tracers as they may lead to different quantitative results.
Irrespective of the radiotracer applied, the fundamental prin-
ciple of targeting the SST2 in atherosclerotic plaque tissue
remains the same. Thus, the relative trend in uptake differ-
ences is expected to be comparable in the ex vivo and
in vivo setting. In an in-vivo situation a larger degree of down
Fig. 8 Uptake of dual-radiotracers in fibrous cap atheroma section; auto-
radiography images showing focal regions of high radiotracer binding for
(a) [111In]In-Danbirt, (b) [99mTc]Tc-Demotate 2, (c) haematoxylin and
eosin stain demonstrating morphology of fibrous cap atheroma section
and corresponding immuno-sections showing positive staining in the fi-
brous cap for (d) leukocytes (LFA-1) and (e) macrophages (SST2) (scale
bar 1 mm)
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scatter is to be expected in the 99mTc window from 111In. This
will subsequently increase the background signal for 99mTc
but should not deter from the image quality when scatter is
corrected for. An increased amount of scattering from the tis-
sue in an in vivo situation would also increase the background.
The administration of two radionuclides will increase the ra-
diation dose to the patient compared with the use of only one.
Since both 99mTc and 111In radionuclides radiate mainly low to
medium energy gamma rays, and the absence of alpha and
beta radiation, radiation issues are not expected when a diag-
nostic amount of these radionuclides are administered to the
patient. In terms of the analysis, in an attempt to normalise the
plaque segments for comparison, the radiotracer uptake was
reported with respect to the weight of each plaque segment. In
one plaque segment, classified with the pathological intimal
thickening phenotype, a negligible degree of inflammation
was present whereby positive area fraction of staining for
LFA-1 and SST2 were 0.09% and 0.01% respectively on im-
munohistochemistry. As a consequence, it is likely that this
ratio approach resulted in a false high uptake (MBq/g) for this
one segment due to the extremely low uptake (MBq) in this
segment and the low weight (g). Due to the small sample size
in this phenotype group (n = 4), a significant difference there-
fore was not reached for [99mTc]Tc-Demotate 2 uptake com-
pared with the fibrous cap atheroma segments.
In conclusion, a dual-isotope acquisition SPECT scanning
protocol was tested to assess the capability of [111In]In-
Danbirt and [99mTc]Tc-Demotate 2 to determine atherosclerot-
ic plaque inflammation and phenotype. The novel [111In]In-
Danbirt detects the presence of multiple leukocyte subsets and
appears to be able to strongly discriminate plaque phenotype
of fibrous cap atheroma from pathological intimal thickening
and fibrocalcific plaque segments. This information provides
a proof of concept basis for the [111In]In-Danbirt as a potential
candidate for total inflammation imaging and plaque pheno-
type classification. Detecting the presence of all leukocytes in
addition to leukocyte subset of proinflammatory macrophages
may further enhance the pathological understanding of the
inflammation involvement in atherosclerosis progression.
Thus, further studies that evaluate the clinical benefit of
utilising this radiotracer in vivo with clinical SPECT scanners
are recommended.
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